Clinical trials: Chiari Malformation Type 2
Ultrasound Therapy; Complications
Intramuscular Heating Rates of a Chattanooga Intelect XT Therapeutic Ultrasound
The purpose of this study is to determine the rate of tissue temperature increase in the triceps surae during an ultrasound treatment using the Chattanooga Intelect Legend XT.
- Trial name
- NCT03816709
- Testing
- Therapeutic Ultrasound
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- North Dakota State University
Venous Leg Ulcers
Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2
This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S.
- Trial name
- NCT01737762
- Testing
- HP802-247, Vehicle
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 155 people
- Sponsor
- Healthpoint
Keratosis
Open-Label Safety Study to Evaluate Imiquimod Cream, 5% for Large Areas of Actinic Keratosis
Actinic keratosis (AK) is a skin condition that shows up on skin routinely exposed to the sun, such as the face, scalp, shoulders, chest, back, arms, and hands.
- Trial name
- NCT00116649
- Testing
- imiquimod cream
- Where
- 32 sites in United States
- Volunteers
- 551 people
- Sponsor
- Graceway Pharmaceuticals, LLC
Actinic Keratosis
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in different doses after once daily treatment for 2 or…
- Trial name
- NCT01820260
- Testing
- Ingenol mebutate gel
- Where
- United States
- Volunteers
- 395 people
- Sponsor
- LEO Pharma
Alzheimer's Disease
Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
This study was designed to evaluate the safety and tolerability of switching from donepezil to an initial dose of 5cm^2 rivastigmine patch formulation in patients with probable Alzheimer's Disease (MMSE 10-24).
- Trial name
- NCT00428389
- Testing
- Rivastigmine 5 cm^2 transdermal patch, Rivastigmine 10 cm^2 transdermal patch
- Where
- 23 sites in United States
- Volunteers
- 262 people
- Sponsor
- Novartis
Hypogonadism
Pharmacokinetics, Metabolism, Efficacy, and Safety Study of Two Testosterone Matrix Transdermal Systems
Watson's testosterone transdermal system delivers male sex hormone through skin for the treatment of men with sex hormone insufficiency.
- Trial name
- NCT01323140
- Testing
- testosterone matrix transdermal system
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Watson Pharmaceuticals
Parkinson's Disease
Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease
The purpose of this trial is to assess whether rotigotine has an effect on the electrical activity of the heart. Moxifloxacin infusion is used as positive control to assess assay sensitivity.
- Trial name
- NCT00292227
- Testing
- Rotigotine, Moxifloxacin infusion
- Where
- 2 sites in South Africa
- Volunteers
- 130 people
- Sponsor
- UCB Pharma
Alzheimer's Disease
A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)
This study is designed to confirm the efficacy, the tolerability, the patient compliance and the caregiver satisfaction with rivastigmine target patch size 10 cm^2 in patients with probable Alzheimer's Disease (Mini-Mental State…
- Trial name
- EXTRA (NCT00622713)
- Testing
- Rivastigmine transdermal patch
- Where
- France
- Volunteers
- 228 people
- Sponsor
- Novartis
Actinic Keratosis
Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
This is a randomised, double-blind, parallel groups, vehicle controlled, 8-week phase 2 trial. The objective is to evaluate efficacy of ingenol mebutate gel 0.06 % after once daily treatment for 2, 3 or 4 consecutive days…
- Trial name
- NCT01998984
- Testing
- ingenol mebutate
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis
Part 1: To identify Maximum Tolerated Dose (MTD) levels of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate the efficacy of LEO 43204 in two doses after once daily treatment for two consecutive…
- Trial name
- NCT02120456
- Testing
- LEO 43204
- Where
- 21 sites in United States, Canada
- Volunteers
- 224 people
- Sponsor
- LEO Pharma
Keratosis, Actinic
A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis
The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm^2 on the face or balding scalp.
- Trial name
- NCT05279131
- Testing
- Tirbanibulin ointment 1%
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
Part 1: To identify Maximum Tolerated Dose (MTD) levels of two formulations of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate efficacy of two formulations of LEO 43204 in two doses after once…
- Trial name
- NCT01922050
- Testing
- LEO 43204 Formulation 1, LEO 43204 Formulation 2, LEO 43204 Formulation 1 Dose X
- Where
- 25 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.
- Trial name
- NCT02361216
- Testing
- Ingenol Mebutate, Vehicle
- Where
- United States
- Volunteers
- 729 people, healthy volunteers welcome
- Sponsor
- LEO Pharma